Gandouling ameliorates liver injury in Wilson's disease through the inhibition of ferroptosis by regulating the HSF1 / HSPB1 pathway
Journal of Cellular and Molecular Medicine · 2024
DOI: 10.1111/jcmm.70018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2024. Verfasst von Chenling Zhao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, China. Hauptthemen laut MEDLINE: Ferroptosis, Heat Shock Transcription Factors, Hepatolenticular Degeneration, Molecular Chaperones. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The National Training Program for Outstanding Western Medical Professionals in Traditional Chinese Medicine, Second Batch (National Letter of Education for Tra…, The Key Research and Development Plan Projects of Anhui Province, The Natural Science Foundation of Anhui Province.
Abstract (Originalsprache)
Ferroptosis, an iron‐dependent form of cell death, plays a crucial role in the progression of liver injury in Wilson's disease (WD). Gandouling (GDL) has emerged as a potential therapeutic agent for preventing and treating liver injury in WD. However, the precise mechanisms by which GDL mitigates ferroptosis in WD liver injury remain unclear. In this study, we discovered that treating Toxic Milk (TX) mice with GDL effectively decreased liver copper content, corrected iron homeostasis imbalances, and lowered lipid peroxidation levels, thereby preventing ferroptosis and improving liver injury. Bioinformatics analysis and machine learning algorithms identified Hspb1 as a pivotal regulator of ferroptosis. GDL treatment significantly upregulated the expression of HSPB1 and its upstream regulatory factor HSF1, thereby activating the HSF1/HSPB1 pathway. Importantly, inhibition of this pathway by NXP800 reversed the protective effects of GDL on ferroptosis in the liver of TX mice. In conclusion, GDL shows promise in alleviating liver injury in WD by inhibiting ferroptosis through modulation of the HSF1/HSPB1 pathway, suggesting its potential as a novel therapeutic agent for treating liver ferroptosis in WD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, China.
- School of Basic Medical Sciences, Wannan Medical College, Wuhu, China.
- Key Laboratory of Xin'An Medicine, Ministry of Education, Hefei, China.
- The Experimental Research Center, Anhui University of Chinese Medicine, Hefei, China.
ORCID-Profile: Chenling Zhao
Förderung
- The National Training Program for Outstanding Western Medical Professionals in Traditional Chinese Medicine, Second Batch (National Letter of Education for Tra…
- The Key Research and Development Plan Projects of Anhui Province
- The Natural Science Foundation of Anhui Province
- The National Natural Science Foundation of China
- Natural Science Foundation of Anhui Province
- National Natural Science Foundation of China
Zitieren
APA
Zhao, C., Chen, J., Tian, L., Wen, Y., Wu, M., Tang, L., Zhou, A., Xie, W., & Dong, T. (2024). Gandouling ameliorates liver injury in Wilson's disease through the inhibition of ferroptosis by regulating the HSF1 / HSPB1 pathway. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70018
Vancouver
Zhao C, Chen J, Tian L, Wen Y, Wu M, Tang L, et al. Gandouling ameliorates liver injury in Wilson's disease through the inhibition of ferroptosis by regulating the HSF1 / HSPB1 pathway. Journal of Cellular and Molecular Medicine. 2024. doi:10.1111/jcmm.70018
BibTeX
@article{Zhao2024,
author = {Zhao, Chenling and Chen, Jie and Tian, Liwei and Wen, Yuya and Wu, Mingcai and Tang, Lulu and Zhou, An and Xie, Wenting and Dong, Ting},
title = {Gandouling ameliorates liver injury in Wilson's disease through the inhibition of ferroptosis by regulating the HSF1 / HSPB1 pathway},
journal = {Journal of Cellular and Molecular Medicine},
year = {2024},
doi = {10.1111/jcmm.70018}
}
EUVIMED